What the company does
Korean Drug makes over-the-counter medicines, including a well-known cold remedy called Haben, as well as prescription drugs targeting central nervous system conditions such as epilepsy, stroke, and Parkinson's disease.
Its products reach patients through pharmacies and hospitals across South Korea. Listed on KOSDAQ, the company's core revenue driver is its central nervous system drug line, which it describes as its lead product category, alongside a broader portfolio spanning digestive, dermatological, antibiotic, and vitamin products.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$45.3M
▼ −14.4% YoY
Operating profit · FY2025
US$5M
▼ −24.4% YoY
Net income · FY2025
US$4.7M
▲ +117.4% YoY
Revenue
- FY2023US$59M
- FY2024US$52.9M
- FY2025US$45.3M
Operating profit
- FY2023US$13.1M
- FY2024US$6.6M
- FY2025US$5M
Net income
- FY2023−US$3.6M
- FY2024US$2.2M
- FY2025US$4.7M
Key ratios (FY2025)
ROE
7.8%
Debt/Eq
13.5%
Op. margin
11.1%
Net margin
10.4%
Rev. YoY
▼ −14.4%
Price charts coming soon
Interactive price history isn't here yet. Would you use it?